Lilly Asia Ventures
Yun Gao, is a Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Yun was most recently Investment Manager at Softbank China Venture Capital (SBCVC). Prior to that, Yun worked as Associate of Business Development and Corporate Strategy at Medtronic China and Senior Analyst at IMS Consulting Group. Yun holds an MBA degree from CEIBS and Bachelor of Medicine Degree from Fudan University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.